101. Efficacy and safety of Danlou tablets in traditional Chinese medicine for coronary heart disease: a systematic review and meta-analysis
- Author
-
WeiLi Mao, Peng Lu, Renhong Wan, Kaili Mao, Yanzhu Lv, Jie Hu, Zhenling Fu, and Jun Wang
- Subjects
Danlou tablet ,coronary heart disease ,randomized controlled trial ,meta-analysis ,complementary alternative therapy ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
BackgroundDanlou tablets exert auxiliary advantages in treating coronary heart disease (CHD), but a summary of evidence-based proof is lacking. This study aims to systematically evaluate Danlou tablets in treating CHD from two aspects, including efficacy and safety.MethodsBy a thorough retrieval of the four English databases, namely, PubMed, The Cochrane Library, Embase, and Web of Science, and the four Chinese databases, namely, CNKI, Wanfang, VIP database, and China Biomedical Literature Service System, we found all randomized controlled trials (RCTs) related to Danlou tablets in treating CHD. The retrieval time was from the construction of the database to April 2022. We engaged two researchers to screen the studies, extract the required data, and assess the risk of bias. We then used RevMan5.3 and STATA.14 software to conduct a meta-analysis. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to evaluate the quality of outcome indicators.ResultsSeventeen RCTs involving 1,588 patients were included. The meta-analysis results are displayed as follows: clinical treatment effect [risk ratio (RR) = 1.22, 95% confidence interval (CI): 1.16, 1.28, P
- Published
- 2023
- Full Text
- View/download PDF